A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and ...

Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

Orbis Medicines raises €90M Series A led by NEA for macrocycle drug development, with backing from Eli Lilly, Cormorant Asset ...

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown ...

San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million ...

The first biopharma venture fund to close in 2025 comes from industry veterans Joe Jimenez and Mark Fishman, two former ...

I-Mab halts CD73 program to focus on givastomig, General Proximity emerges with $16M for undruggable proteins, PBS Biotech raises $17M, Citius explores sale ...

Oculis' OCS-05 succeeds in Phase 2 trial for acute optic neuritis, showing improved vision and retinal measures. FDA clears ...

Iambic Therapeutics has hired a CFO, poaching an executive who helped engineer the first big merger in the AI-driven biotech ...

Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.